Court Rules that the Patents Asserted against Dexcom CGM Systems are Invalid
August 23 2019 - 4:25PM
Business Wire
The U.S. District Court for the District of Oregon has granted
Dexcom's (NASDAQ:DXCM) motion for summary judgment invalidating all
asserted claims in the two remaining patents asserted against it by
WaveForm Technologies, Inc., a subsidiary of AgaMatrix.
Granting Dexcom's motion for summary judgment that the asserted
claims of two patents are invalid for “indefiniteness,” the
District Court handed Dexcom a complete victory in the lawsuit,
filed in 2016 and initially asserting three patents. Dexcom earlier
had defeated one patent in a proceeding in the United States Patent
and Trademark Office.
“We are extremely pleased by the Court’s ruling that Dexcom’s
innovative and important technology helping people with diabetes is
not in violation of WaveForm’s patents and that the patents should
never have been granted in the first place,” said Patrick Murphy,
Senior Vice President and General Counsel. “This case and outcome
demonstrate Dexcom’s commitment to defend itself against meritless
infringement allegations,” he added.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, California, is
developing and marketing continuous glucose monitoring systems for
ambulatory use by people with diabetes and by healthcare providers
for the treatment of people with diabetes.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190823005352/en/
DexCom, Inc.: Steven R. Pacelli Executive Vice President,
Strategy and Corporate Development (858) 200-0200
www.dexcom.com
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Aug 2024 to Sep 2024
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Sep 2023 to Sep 2024